Nasdaq GlobeNewswire

Apricus Biosciences Confirms Clinical Strategy for Its Novel Treatment for Symptomatic Secondary Hypogonadism Fispemifene

Del

SAN DIEGO, 2015-12-01 18:49 CET (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reaffirmed its regulatory and clinical strategy for the development of fispemifene in response to the Complete Response Letter issued to Repros Therapeutics Inc. (RPRX) by the Food and Drug Administration (FDA). Apricus is developing fispemifene, a SERM (selective estrogen receptor modulator) for the treatment of sexual dysfunction in men with symptomatic secondary hypogonadism.

"Apricus has worked with the FDA to develop our clinical strategy for fispemifene," commented Barbara Troupin, M.D., Chief Medical Officer of Apricus. "For our ongoing Phase 2b study, we developed a protocol that addresses the FDA's suggestions for clearly defining the target patient population, designating clinical benefits which are both important and relevant to the target population, and using symptom-based endpoints aimed at assessing those specific benefits in this population. As a result, we believe we are well-positioned to bring a first-in-class SERM product to the U.S. market."

Apricus expects to report results from the Phase 2b fispemifene trial in the first quarter of 2016 and, if successful, will continue to work closely with the FDA to plan registration studies of fispemifene in 2016.

Phase 2b Trial Design

The Phase 2b proof-of-concept clinical trial is a randomized, double-blind, placebo-controlled, parallel arm, multi-center study in up to 160 hypogonadal men aged 18 to 64 who present with sexual dysfunction related to secondary hypogonadism, or low levels of testosterone. The study will evaluate the safety and tolerability of oral fispemifene, and will assess the effects of treatment on the sexual symptoms using patient reported outcome (PRO) endpoints. The study will also assess relevant pharmacodynamic and pharmacokinetic parameters to evaluate the ability of fispemifene to endogenously increase the serum testosterone level.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus recently completed enrollment in its Phase 2b trial for fispemifene, a selective estrogen receptor modulator for the treatment of symptomatic male secondary hypogonadism, and plans to conduct additional studies in other urological conditions. Apricus has completed a Phase 2a trial for RayVa™, its product candidate for the treatment of the circulatory disorder Raynaud's phenomenon, and plans to conduct additional clinical trials in patients with Raynaud's phenomenon secondary to scleroderma. Apricus' lead commercial product, Vitaros®, for the treatment of erectile dysfunction, is approved in Europe and Canada and is being commercialized in several countries in Europe. Apricus recently in-licensed the U.S. development and commercialization rights for Vitaros from Allergan. Apricus' marketing partners for Vitaros include Laboratoires Majorelle, Bracco S.p.A., Hexal AG (Sandoz), Takeda Pharmaceuticals International GmbH, Recordati Ireland Ltd. (Recordati S.p.A.), Ferring International Center S.A. (Ferring Pharmaceuticals) and Mylan NV. Apricus' second-generation room temperature Vitaros is currently under development.

For further information on Apricus, visit http://www.apricusbio.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, as amended. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things: Apricus' development activities for fispemifene, including the Phase 2b protocol addressing the FDA's suggestions for such trial, a development pathway and Apricus' ability to move fispemifene into later stage clinical development, and the effects of Repros Therapeutics's complete response letter on such clinical development; the timing and results of the Phase 2b clinical trial to evaluate fispemifene for the treatment of symptomatic male secondary hypogonadism; the potential timing of a competitor's SERM product being approved by the FDA; and the potential timing of any new drug application, or NDA, submission by Apricus. Actual results could differ from those projected in any forward-looking statements due to a variety of reasons that are outside the control of Apricus, including, but not limited to: the timing and results of the ongoing Phase 2b clinical trial of fispemifene, Apricus' ability to receive feedback from the FDA on the development of fispemifene and, based on such feedback, further develop fispemifene for the treatment of symptomatic male secondary hypogonadism or other urological conditions, as well as the timing of such events; Apricus' ability to carry out further clinical studies for fispemifene, as well as the timing and success of the results of such studies; issues raised by the FDA in Repros Therapeutics;s complete response letter affecting the development of and regulatory approval for fispemifene; Apricus' ability to raise additional funding that it may need to continue to pursue its commercial and business development plans; and Apricus' ability to obtain the requisite governmental approval for fispemifene. These forward-looking statements are made as of the date of this press release, and Apricus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in Apricus' most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC's website at www.sec.gov or without charge from Apricus.

         CONTACT: Institutional / Retail Investors: Matthew Beck
         mbeck@troutgroup.com
         The Trout Group LLC
         (646) 378-2933

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

InnovMetric Acquires Prefixa Vision Systems21.2.2018 21:22Pressemelding

Consolidates its market presence in Mexico QUEBEC CITY, Feb. 21, 2018 (GLOBE NEWSWIRE) -- InnovMetric Software Inc., the leading provider of universal 3D metrology software solutions, today announced the acquisition of Prefixa Vision Systems, its PolyWorks® Master distributor in Mexico, following five years of successful cooperation. "The growth of the automotive industry in Mexico has been so phenomenal in recent years that in our latest fiscal year Mexico became the 5th largest PolyWorks market in the world. InnovMetric is deeply committed to expanding its local technical expertise to assist its Mexican customers in their successful migration to the PolyWorks universal 3D metrology software platform," said Marc Soucy, President of InnovMetric. The acquisition allows InnovMetric to expand the capabilities of its local subsidiary, PolyWorks Mexico, which include supporting and training Mexican customers and assisting local metrology hardware partners. PolyWorks Mexico will also market

Taconic Biosciences Announces the Formation of Scientific Advisory Board21.2.2018 19:13Pressemelding

RENSSELAER, N.Y., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated services, announced the formation of its Scientific Advisory Board (SAB) with the initial appointments of J. Victor Garcia, PhD, Andrew Goodman, PhD, and David Hill, PhD. The SAB will collaborate with Taconic's management in providing scientific insight and guidance on the evolution of the company's product and service portfolios. Capitalizing on Taconic's existing leadership in both the microbiome and immuno-oncology spaces, the SAB members bring complementary expertise to continue to drive innovation in these and other research areas. "Discovery and pre-clinical animal models continue to move toward highly-complex and high-value translational models. To continue to provide the best solutions for our customers, it is essential for Taconic to have guidance from prominent scientific experts as we develop and validate new models and services," sha

SD-WAN Market Leader Aryaka Further Expands UK and EMEA Market Reach with Intergence Partnership21.2.2018 16:01Pressemelding

Partnership Enables More UK and EMEA Enterprises to Adopt Global SD-WAN as-a-Service LONDON, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Aryaka®, the leading global SD-WAN provider, today announced that Cambridge, UK-based Intergence will deploy Aryaka's global SD-WAN solution to enhance global connectivity and application performance for its enterprise customers with offices in the UK and Europe. Partnering with Aryaka strengthens Intergence's infrastructure services proposition for its global enterprise customers. Intergence comprises a team of IT infrastructure experts that help organizations realize their digital transformation objectives. Formed in 2003, the company uses innovative technologies like its Stratiam(TM) solution to provide CIOs with insights about IT performance and the customer's digital experiences, and to simplify complex IT problems. Intergence's infrastructure services provide IT leaders with greater flexibility, agility, and cost efficiency. The partnership will enable In

TrueCommerce Dynamics 365 Solution Featured on Microsoft AppSource21.2.2018 16:00Pressemelding

TrueCommerce Solution Delivers Powerful Supply Chain Integration Capabilities to Dynamics 365 Community PITTSBURGH, Feb. 21, 2018 (GLOBE NEWSWIRE) -- TrueCommerce, a global provider of trading partner connectivity and integration solutions, has announced today that its Microsoft Dynamics 365 solution is available on Microsoft AppSource. Built exclusively for and within the native Dynamics 365 platform, the embedded solution connects directly with TrueCommerce's global commerce network, offering immediate access to more than 92,000 pre-connected retailers, marketplaces, distributors, vendors and logistics providers. "Our solution for Dynamics 365 offers a multi-company, multi-deployment architecture that scales to support complex enterprise requirements," said TrueCommerce president Ross Elliott. "We are excited to be selected as one of the few EDI solutions to be featured on Microsoft AppSource, recognition of having achieved Microsoft's highest standards for quality and reliability fo

Colliers International Named to IAOP® Global Outsourcing 100 List for 13th Consecutive Year21.2.2018 15:00Pressemelding

International Association of Outsourcing Professionals® Honors Colliers in Its Annual Listing of the World's Best Outsourcing Service Providers TORONTO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Leading global commercial real estate services firm Colliers International Group Inc. (NASDAQ:CIGI) (TSX:CIGI) is pleased to announce that it has again been selected for The 2018 Global Outsourcing 100 list by IAOP®, an honor the company has earned for 13 straight years, more than any other real estate services provider. Colliers has been named to the list each year since its inception. Colliers is committed to leadership in the global outsourcing industry and has a proven track-record in the space. The company's outstanding growth continues through a focus on maintaining the most collaborative and creative culture in the industry, allowing clients to accelerate their success by sharing its market-leading expertise. "We are honored to again receive this prestigious recognition from IAOP," said Dylan Ta

Announcing North America's Most Advanced Radio Access Network Solution by GCI in Collaboration with Altiostar21.2.2018 15:00Pressemelding

ANCHORAGE, Alaska, Feb. 21, 2018 (GLOBE NEWSWIRE) -- GCI, Alaska's largest telecommunications provider announced today that it has selected Altiostar to supply virtualized RAN (vRAN) technology to support GCI's LTE-Advanced network deployment and to lay the foundation for 5G and IoT. The technology will allow GCI to expand network coverage and improve capacity, and thus enhance end-user experience. Over the last 12 months GCI has been conducting field trials in Anchorage and Fairbanks with this solution from Altiostar, and this contract award is the result of this validation of the vRAN technology. Altiostar will introduce its LTE-Advanced technologies such as 4x4 MIMO and Multi-band Carrier Aggregation to significantly enhance end user experience for data applications and better voice quality using Voice over LTE (VoLTE). LTE 4x4 MIMO enables better mobile broadband coverage and data throughput for GCI subscribers, and increased spectral efficiency for GCI. GCI customers will benefit

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom